Vickers, Mark A.Wilkie, Gwen M.Robinson, NicolasRivera, NadjaHaque, TanzinaCrawford, Dorothy H.Barry, JacquelineFraser, NeilTurner, David M.Robertson, VictoriaDyer, PhilFlanagan, PeterNewlands, Helen R.Campbell, JohnTurner, Marc2014-12-122014-12-122014-11Vickers, M A, Wilkie, G M, Robinson, N, Rivera, N, Haque, T, Crawford, D H, Barry, J, Fraser, N, Turner, D M, Robertson, V, Dyer, P, Flanagan, P, Newlands, H R, Campbell, J & Turner, M 2014, 'Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease', British Journal of Haematology, vol. 167, no. 3, pp. 402-410. https://doi.org/10.1111/bjh.130510007-1048ORCID: /0000-0002-3154-1040/work/76975324http://hdl.handle.net/2164/4107Funded by Wellcome Trust Translational Award SNBTS9205684engSDG 3 - Good Health and Well-beingcell therapyEpstein-Barr viruscytotoxicitylymphoproliferative diseaseRC Internal medicineWellcome Trust102610RCEstablishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative diseaseJournal article10.1111/bjh.130511673